Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib

Leuk Res. 2008 Oct;32(10):1626-8. doi: 10.1016/j.leukres.2008.01.015. Epub 2008 Mar 5.

Authors

M Breccia, M Muscaritoli, L Cannella, C Stefanizzi, A Frustaci, G Alimena

PMID: 18321570
DOI: 10.1016/j.leukres.2008.01.015

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antineoplastic Agents / therapeutic use*
Benzamides
Blood Glucose / analysis*
Dasatinib
Diabetes Complications / drug therapy*
Diabetes Mellitus, Type 2 / blood
Diabetes Mellitus, Type 2 / complications
Diabetes Mellitus, Type 2 / drug therapy
Fasting
Female
Humans
Imatinib Mesylate
Leukemia, Myeloid, Accelerated Phase / complications
Leukemia, Myeloid, Accelerated Phase / drug therapy*
Piperazines / therapeutic use*
Protein Kinase Inhibitors / therapeutic use
Pyrimidines / therapeutic use*
Thiazoles / therapeutic use*
Treatment Failure

Substances

Antineoplastic Agents
Benzamides
Blood Glucose
Piperazines
Protein Kinase Inhibitors
Pyrimidines
Thiazoles
Imatinib Mesylate
nilotinib
Dasatinib